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ABSTRACT
The ARID (A–T Rich Interaction Domain) is a helix–
turn–helix motif-based DNA-binding domain, con-
served in all eukaryotes and diagnostic of a family
that includes 15 distinct human proteins with import-
antrolesindevelopment,tissue-specificgeneexpres-
sion and proliferation control. The 15 human ARID
family proteins can be divided into seven subfamilies
based on the degree of sequence identity between
individual members. Most ARID family members
have not been characterized with respect to their
DNA-binding behavior, but it is already apparent
that not all ARIDs conform to the pattern of binding
AT-rich sequences. To understand better the diver-
gent characteristics of the ARID proteins, we under-
took a survey of DNA-binding properties across the
entire ARID family. The results indicate that the
majority of ARID subfamilies (i.e. five out of seven)
bind DNA without obvious sequence preference.
DNA-binding affinity also varies somewhat between
subfamilies. Site-specific mutagenesis does not sup-
port suggestions made from structure analysis that
specific amino acids in Loop 2 or Helix 5 are the main
determinants of sequence specificity. Most probably,
this is determined by multiple interacting differences
across the entire ARID structure.
INTRODUCTION
TheARID(A–TRichInteractionDomain)isahelix–turn–helix
motif-basedDNA-bindingdomain,conservedinalleukaryotes
and diagnostic of a family that comprises 15 distinct human
proteins. ARID proteins, although diverse in function, all
appear to play important roles in development, tissue-speciﬁc
geneexpressionand cellgrowth regulation[reviewed in(1,2)].
The ARID consensus sequence, which spans about 100 resi-
dues, was ﬁrst identiﬁed as a DNA-binding domain in the
mouse B cell-speciﬁc transcription factor, Bright (3), and in
the Dead ringer protein (Dri) of Drosophila melanogaster
(4). Dri and Bright were each isolated in searches designed
to detect proteins binding selectively to AT-rich sequences.
RecognitionoftheBright/Driconsensusdeﬁnedtheparameters
ofanewDNA-bindingdomain,andthepropertiesofBrightand
Driinspireditsname.MRF-1andMRF2, which bindtheCMV
enhancer and repress its activity, are also ARID-containing
proteins that bind selectively to AT-rich sites (5,6).
Although the ﬁrst studied ARID-containing proteins bind
preferentially to AT-rich sites, this behavior does not appear to
be an intrinsic feature of the domain. Most ARID family
members have not been characterized with respect to their
DNA-binding behavior, but it has become apparent that not
all ARIDs conform to the pattern of binding AT-rich
sequences. p270 is a human ARID-containing protein that
is an integral member of SWI/SNF-related chromatin remo-
deling complexes (7–10). p270 contains a complete ARID
consensus and binds DNA with an afﬁnity similar to Dri,
but is unable to select oligonucleotides of any preferred
sequence from a random pool (9,11). Lack of sequence spe-
ciﬁcity has been shown independently for the ARID family
member, Osa, the closest Drosophila counterpart of p270 (12).
The ARID structures for MRF2, Dri, p270 and its yeast
counterpart SWI1 have been studied by NMR (13–16). Des-
pite the high degree of conservation in the domain, at least
three distinct structural patterns are recognized: MRF2 and
SWI1 both have six helices and two loops. Dri has one
more helix on each end formed by sequences outside the
consensus and a b-sheet instead of a ﬂexible loop between
Helix 1 and Helix 2. p270 has an additional short N-terminal
helix, but no C-terminal helix or any b-sheets. The structures
of the MRF2, Dri and p270 ARIDs have also been solved in
complex with DNA (15,17,18). All studies agree that the
ARID binds DNA via both the major and the minor grooves,
and that major groove contacts are made through residues in
Loop 2 and/or Helix 5.
The human ARID family can be divided into seven
subfamilies based on the degree of sequence identity
between individual members (Figures 1 and 2). The diverse
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doi:10.1093/nar/gki145characteristics of the ARID proteins studied so far prompted a
survey of DNA-binding properties across the entire ARID
family. The results indicate that the majority of ARID sub-
families (i.e. ﬁve out of seven) bind DNA without obvious
sequence preference. DNA-binding afﬁnity also varies
somewhat between subfamilies. Site-speciﬁc mutagenesis
does not support suggestions made from structure analysis
that speciﬁc amino acids in Loop 2 or Helix 5 are the main
Figure 1. Alignment of human ARID sequences. The amino acid sequences of the ARID region of the 15 human ARID family members are shown. The shading
indicatestheboundariesofthea-heliceswhere thestructuraldataareknown(13,15,17).Thesequencesofthe ARIDsofD.melanogasterDri,whichhasanARID3-
classsequenceandS.cerevisieae SWI1,areshownaswell becausestructuraldataisalso availableforthem(14,16,18).Helicesare labeledatthe topfromH0to H7.
ThelocationofLoops1and2andtheb-sheet(whichsofarisfoundonlyintheARID3-classsequence)arealsoshown.ThefiveinvariantresiduesoftheARIDregion
are shown in red. Part of the ‘extended ARID’ that characterizes the ARID3 subfamily is shown to indicate the degree of homology in this region. The ARID2 and
ARID3Csequencesbeginattheinitialmethionineoftheprotein.ThesequenceswerealignedusingtheClustalW1.8multiplesequencealignmentprogram(50).The
computer-generated alignment was modified slightly to reflect higher level structural data.
Figure2.ThehumanARIDfamilyofproteins.Genomesequencingreveals15ARID-containingproteinsinhumans.TheARIDfamilyproteinscanbegroupedinto
subfamiliesbasedontheirsimilaritytoeachotherwithintheARIDdomain.Thenomenclaturedescribedherereflectsthissubclassificationofthefamilyandclarifies
their relationships to each other. A subset of ARID-containing proteins also contains JmJN and JmJC domains, and the proposed nomenclature reflects these
relationships as well. Within the proposed subgroups of the ARID family, members typically have 70–85% identity within their ARID sequences, while across
subgroupsidentitywithintheARIDsequencedropsto 25–30%.The15humanARIDfamilyproteinsarerepresentedbyopenbarsandarealignedaccordingtothe
positionoftheARIDsequence(indicatedinyellow).Therelativepositionsofotherwell-characterizeddomainsandmotifsarerepresentedbydifferentlycoloredbars
orboxesintheappropriateproteinstructuresandidentifiedatthebottomofthefigure.Theaminoacid(aa)lengthofeachproteinisshowntotherightofthebar.The
presence of additional motifs was identified through the Pfam database (51).
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determined by multiple interacting differences across the
entire ARID structure.
MATERIALS AND METHODS
Plasmids
GST fusion constructs. The p270 fusion protein experiments
were originally performed with the product of plasmid pNDX
(9). For the mutagenesis studies, a shorter expression construct
designated pNDB8 was generated to be more comparable in
size with the Dri fusion peptide. The NDB8 plasmid expresses
amino acids 958–1188 of p270 (numbering is according to the
sequence at accession number NP_006006). The Dri fusion
protein is the product of p410 (4), which was kindly provided
by R. Saint (University of Adelaide, Australia) and expresses
Dri residues 258–410 (according to accession number
AAB05771).
A series of plasmids was assembled expressing GST-fusion
proteins containing the ARID regions of representative mem-
bers of ARID subfamilies. The MRF2 fusion protein is the
product of pMRF2-GST, which was constructed by ligating a
BamHI/SalI restriction fragment from the insert of plasmid
MRF2pQE30 [(13); kindly provided by Yuan Chen at the
Beckman Institute, City of Hope, Duarte, CA] into the
pGEX4T vector (Pharmacia Biotech). A construct containing
the ARID domain of human RBP1, called GST–ARID (19),
was provided Dr Philip Branton (McGill University, Montreal,
Canada). The ARID2 sequence was generated by RT–PCR
from HepG2 cells using oligonucleotides ARID2-F (50-
ATAATGGCAAACTCGACGGGGAAG) and ARID2-R
(50-CACCCCGGCATTAGCAAGTAGTAA) to yield a
630 bp fragment that encodes amino acids 1–209 according
to accession number XP_350876. The fragment was cloned
into pCR2.1-TOPO vector (Invitrogen) to make ARID2–
TOPO. The EcoRI fragment of ARID2–TOPO was sub-cloned
intothe EcoRI siteof pGEX-4T1 (Pharmacia Biotech) tomake
pARID2-pGEX. The PLU-1 sequence was generated by RT–
PCR from MCF-7 cells using oligonucleotides PLU-1 For (50-
TTCGCGGACCCCTTCGCTTTCA) and PLU-1 Rev short
(50-AATATTCATGGCCTCTGCTCTC). The reaction gener-
ated a 597 bp fragment extending from nucleotide 213 to 810
(according to accession number AJ132440.1), which was cloned
into the pCR2.1-TOPO vector to create pPLU-1-TOPO. A
PLU-1 containing BstXI restriction fragment was released
from the vector, blunted with T4 DNA polymerase,and ligated
with SmaI digested pGEX-4T1 to generate pPLU-1-GST.
pPLU-1-GST generates a GST-fusion protein containing
amino acids 42–241 of PLU-1 according to accession number
CAB43532. An RBP2 sequence-containing PCR fragment
was generated with primers RBP2-F-Xho (50-AGACTCGA-
GTTCACAGATCCGCTCAGCTTTATC) and RBP2-R-Xho
(50-AGACTCGAGTTTAGGACACCTCCAGTCTCCTTT)
from the plasmid template pCMV-HA-RBP2 (provided by
Philip Branton), and cloned into the pCR2.1-TOPO vector
to create pRBP2-TOPO. An XhoI restriction fragment from
the RBP2-TOPO insert was blunted with Klenow polymerase
and ligated with SmaI-digested pGEX-4T3 to create the plas-
mid pRBP2-pGEX. This construct produces a GST-fusion
protein containing RBP2 amino acids 29–339 (accession
number NP_005047). The jumonji fragment was ampliﬁed
by PCR from a murine brain cDNA library in a vector back-
bone of pACT-2 (Clontech) that was kindly provided by
Dr Premkumar Reddy (Fels Institute, Temple University
School of Medicine, Philadelphia, PA). jumonji-TOPO
was generated by PCR using the primers jumonji For (50-
AGAGAATTCTGTGAAAATCGTTCTACCTCGCAA) and
jumonji Rev (50-AGACTCGAGATGACAGTCCTTCTCTT-
CCACTAA) to generate a 1030 bp fragment extending
from nucleotide 1750 to 2780 according to accession number
D31967. The PCR fragment was cloned into the pCR2.1-
TOPO vector to create pjumonji-TOPO, excised from the
vector with EcoRI and XhoI, and cloned into EcoRI/XhoI-
digested pGEX-4T1 to create pjumonji-pGEX-4T1. This con-
struct creates a GST-fusion protein containing amino acids
519–858 of jumonji (accession number NP_068678). This
is the only case where a murine sequence was used in the
subfamily constructs, but the mouse and human proteins are
92% identical across the coding span of the insert.
In vitro translation constructs. The p270 pNE9-B2 in vitro
expression plasmid and the Dri in vitro expression plasmid
pDriT2 were described previously (11).
Generation of amino acid substitution mutations
All mutations were generated using the QuikChange (Strata-
gene) system according to the manufacturer’s instructions.
The forward primers used to generate amino acid substitutions
in pNE9-B2 or pDriT2 are as follows (the substituted bases are
underlined):
p270.P1042A: GCATGACAAATCTGGCTGCTGTGGG-
TAGGAAACC
p270.W1073A: GGTCAACAAGAACAAAAAAGCGCG-
GGAACTTGCAACC
p270.Y1096A: CCTTGAAAAAGCAGGCTATCCAGTG-
CTCTATGC
Dri.P306A: CCGATCAATCGGCTGGCGATAATGGCC-
AAATCGG
Dri.W337A: CAACAAGAAGCTGGCGCAGGAGATCA-
TCAAGGGGC
Dri.Y361A: CCCTGCGCACCCAAGCCATGAAGTATC-
TGTACCCG
The remaining mutations were generated in p410 or pNDB8.
The forward primers used to generate amino acids substitu-
tions are as follows (the substituted bases are underlined):
Dri.SSS: GCCCTCCAGCATCTCCAGTGCCGCCTCCT-
CCCTGCGCACCC
p270.TFT:GTGGGCACATCAACCAGTGCTGCCTTCA-
CCTTGAAAAAGCAG
Deletion mutants were generated by a loop-out technique
using a primer designed to form a junction between residues at
the borders of the deletion. The sequence of the forward
primers used to generate the deletions is as follows (the
nucleotides that mark the boundaries of the loop-out are
underlined):
Dri.DC: GAATCTGAGCACGCAGATGCCGATGACG
p270.DN:GGGACACCCAAGACAGAAATCACCAAGT-
TGTATGAGCTG
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sequence to be replaced, and then looping-in the desired
sequence. The sequence of the forward primers used to gen-
erate the deletions is as follows (the nucleotides that mark the
boundaries of the loop-out are underlined):
L2.H5.out: CGGGAACTTGCAACCAACCTCTTGAAA-
AAGCAGTATATCCAG
H4.out: GGATTGACTCAGGTCAACAAGAACAAACT-
CCACCTGCCCTCCAGC
The sequence of the forward primers used to generate the
insertions is as follows (the nucleotides that form the loop-
in are underlined):
L2.H5.in: GCAACCAACCTCCACCTGCCCTCCAGCA-
TCACCAGTGCCGCCTTCACCTTGAAAAAGCAG
H4.in: GTCAACAAGAACAAACTGTGGCAGGAGAT-
CATCAAGGGGCTCCACCTGCC
The sequence changes and the integrity of the sur-
rounding sequences for all mutants were veriﬁed by DNA
sequencing.
Sequence-specific selection of DNA
GST-fusion proteins were used in pull-down assays with a
pool of Lambda DNA restriction fragments. The assay was
performed as described previously (11,12). Restriction frag-
ments were ﬁlled in with [a-
32P]dATP. Labeled DNA (0.8 mg)
was incubated with 50 ng of GST-fusion protein bound to
glutathione–agarose beads for 1 h at 4 C in Lambda DNA-
binding buffer [20 mM HEPES (pH 7.6), 1 mM EDTA (pH 8),
10 mM (NH4)2SO4, 0.2% Tween-20, 1 mM DTT, 25 mg/ml
BSA and 25 mg/ml poly(dI–dC)] plus varying amounts of KCl,
as indicated in the text. The beads were washed three times
with Lambda DNA-binding buffer minus DTT, BSA and
poly(dI–dC). Bound DNA was eluted by boilinginFormamide
loading buffer (90% formamide, 1· TBE, 0.04% bromophenol
blue and 0.04% xylene cyanol), separated on a 6% sequencing
gel and visualized by autoradiography.
For the oligonucleotide competition assays, 10 ng of
32P-end-labeled double-stranded oligonucleotide was incu-
bated with 100 ng of GST-fusion protein bound to glutathione
beads in the Lambda DNA-binding buffer containing
50 mM KCl, 100 mg of salmon sperm DNA and varying
amountsofunlabeleddouble-strandedcompetitoroligonucleo-
tide, as indicated in the text. The beads were washed and the
bound DNA was eluted and visualized as described above.
In vitro translation and DNA cellulose
chromatography
The wild-type and mutant plasmid constructs were used to
generate 35S-methionine-labeled polypeptides using the
TNT-coupled reticulocyte system (Promega). In vitro trans-
lated proteins were diluted in one bed volume (0.5 ml) of
Column loading buffer [10 mM potassium phosphate
(pH 6.2), 0.5% NP40, 10% glycerol, 1 mM DTT, aprotinin
(1 mg/ml), pepstatin (1 mg/ml), leupeptin (1 mg/ml)], and
applied to native DNA cellulose columns (Pharmacia). The
protein sample was passed through the column twice. The
columns used were Poly-Prep Chromatography Columns
(Bio Rad catalog number 731-1550). Unbound material is
designated ﬂow-through (FT). The columns were then
washed multiple times with 1.0 bed volume column-loading
buffer containing 50 mM NaCl (these are the 50 mM
wash fractions), and eluted stepwise with column-loading
buffer adjusted to contain increasing concentrations of
NaCl from 100 to 800 mM, as indicated in the text. Fractions
were analyzed by SDS–PAGE. The signal on the dried gel
was quantiﬁed using a phosphorimager (Fuji) and associated
software.
RESULTS
ARID subfamilies vary in sequence specificity
and DNA-binding affinity
Human and mouse ARID-containing proteins can be classiﬁed
into seven subfamilies: ARID1, ARID2, ARID3, ARID4,
ARID5, JARID1 and JARID2. Within each designated sub-
family, the degree of identity within the ARID regions is very
high, ranging from 70 to 83% (Figure 1). In contrast, identity
between ARID regions across subfamilies is <30%. Members
within subfamilies generally also show clear relationships out-
side the ARID, as shown in Figure 2. These subclassiﬁcations
are the basis for the current nomenclature of the ARID family,
which has recently been accepted by the HUGO Gene
Nomenclature Committee (HGNC) and the Mouse Genomic
Nomenclature Committee (MGNC).
The DNA-binding properties of only a few ARID family
members have been reported. Drosophila Dri and its murine
ortholog Bright (ARID3A), as well as human MRF2
(ARID5B) all bind AT-rich sites selectively (3,4,6). However,
human p270 (ARID1A), the closely related human protein
ARID1B, and their apparent Drosophila and yeast counter-
parts, Osa and SWI1, all bind DNA without sequence
speciﬁcity (9,11,12,20). A better understanding of the biolo-
gical role of the ARID family will require a more thorough
understanding of the distribution of sequence-speciﬁc
DNA-binding properties among the individual members.
We therefore undertook a survey designed to determine the
DNA-binding properties of at least one member of each ARID
subfamily.
BecauseaminoacididentitywithintheARIDconsensusisso
high within subfamilies, originally a single member of each
subfamily was selected to test for sequence speciﬁcity.
Recombinant GST-fusion proteins were constructed using
sequences that include the ARID domain of each protein
examined. The sequence speciﬁcity of each protein was then
examined in a DNA pull-down assay. This assay allows
each protein access to a pool of Lambda DNA restriction
fragments of varying size and sequence. As shown in
Figure 3, Dri (the Drosophila counterpart of ARID3A) and
MRF2 (ARID5B) bind in a sequence-speciﬁc manner in this
assay, selectively binding to some fragments and not others.
Selectivityforspeciﬁcfragmentsbecomesmorepronouncedin
more stringent binding conditions (i.e. increased salt con-
centrations). Slight differences in the selected fragments
between Dri and MRF2 probably reﬂect the fact that the
two proteins select slightly different consensus sites in vitro
(3,4,6). The major bands consistently selected by Dri in this
assay are indicated by markers to the right of the Dri panel
in Figure 3. In contrast to Dri, p270 (ARID1A) binds in a
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showing selectivity only for longer fragments (>200 bp) at
higher salt concentrations, presumably because longer frag-
ments offer multiple binding sites. Despite the differences in
sequence speciﬁcity, all three ARID proteins show similar
afﬁnities for DNA. These patterns have been documented
previously (4,6,9,11), and are shown here for ease of com-
parison and as controls for the assay. The ARID1B protein
has also been compared directly with p270, and found to
bind without speciﬁcity (20).
The assay was used to examine the sequence speciﬁcity
and DNA-binding afﬁnity of representative members from
each of the four remaining ARID subfamilies (Figure 4).
ARID2 is the only member of its subfamily. A full-length
human cDNA has not been reported thus far, but Genbank
sequences predict an ARID consensus sequence at the
N-terminus of the ARID2 gene product. Isolation of N-
terminal cDNA sequence by RT–PCR from the human
liver cell line HepG2 conﬁrms the presence of the ARID
in the transcript (accession number AY727870.1). Studies
on mammalian ARID2 have not yet been reported, but the
protein is an apparent ortholog of the Drosophila ARID
protein BCDNA:GH12174 (CG3274). Both proteins contain
an RFX domain, which is an additional DNA-binding domain
[reviewed in (21)]. Interestingly, the protein product of
Drosophila BCDNA:GH12174 was recently found to be a
component of the SWI/SNF-like complex PBAP, and was
designated BAP170 (22). This complex is distinguished from
the BAP SWI/SNF-like complex in part by its lack of Osa.
This ﬁnding extends the role of ARID-containing subunits as
components of SWI/SNF-related chromatin-remodeling com-
plexes. Analysis of ARID2 in the DNA pull-down assay
(Figure 4) indicates that it binds DNA without sequence
speciﬁcity, like all other known ARID-containing compo-
nents of SWI/SNF-related complexes.
ARID4 subfamily DNA-binding activity is represented here
by RBP1 (ARID4A). Amino acid identity within the ARID
consensus is 75% between RBP1 (ARID4A) and RBP1L1
(ARID4B), the only other member of this class. The assay
shown in Figure 4 indicates that RBP1 also binds DNA with-
out sequence speciﬁcity. RBP1 has been characterized as a
repressor of E2F-dependent transcription recruited by the reti-
noblastoma protein (pRb) and can recruit histone deacetylase
(19,23,24). RBP1L1 (syn.: SAP180) is also able to repress
transcription, at least when tethered to DNA through the
Gal DNA-binding domain (25). Both RBP1 and RBP1L1/
SAP180 have been found in association with the mSIN3-
histone deacetylase complex (19,25).
JARID1 is the largest ARID subfamily. It contains four
highly homologous members. RBP2 (JARID1A) can enhance
nuclear hormone receptor transactivation in reporter assays
(26). PLU-1 is highly expressed in breast cancers, and in
reporter assays has transcriptional repressor properties (27).
SMCX (JARID1C) and SMCY (JARID1D) are thought to be
regulators of minor histocompatability antigen (28,29). The
four JARID1 proteins share 83% amino acid identity within
the ARID and are highly related across their full sequences.
This subfamily, in common with JARID2, contains highly
conserved JmJN and JmJC domains. The proposed nomen-
clature reﬂects these relationships. The function of JmJN and
JmJC domains is not yet clear, but they exist in proteins other
than ARID family members (30,31). Two representatives of
the JARID1 subfamily were chosen for analysis. A second
subfamily member was included for two reasons. First,
amino acid identity between PLU-1 (JARID1B) and the other
three members of this subfamily varies more than is typical
within subfamilies in the Loop 2 and Helix 5 region of the
ARID sequence (see Figure 1). PLU-1 has a histidine within
the Helix 5 region at a position where the other members of
this subfamily contain a leucine. This region is the major
groove interaction site in other ARID members and could
be expected to play an important role in sequence recognition.
Second, PLU-1 is expressed in a highly tissue restricted
manner in contrast to other JARID1 members, which are
broadly expressed [reviewed in (1)]. RBP2 (JARID1A) was
chosen to represent the more typical members of this sub-
family. As shown in Figure 4, both RBP2 (JARID1A) and
PLU-1 (JARID1B) bind DNA with little or no discernible
sequence speciﬁcity.
The panel was completed by testing jumonji (JARID2), the
only member of its subfamily. jumonji is developmentally
Figure 3. DNA-binding properties of the ARID family. Lambda phage DNA
was digested with EcoRI, HindIII and Sau3AI to generate a large DNA
oligonucleotide pool predicted to contain 128 fragments ranging in size
from 12 to 2225 bp. The fragments were filled in with [32P]dATP,
incubated with GST-fusion proteins containing the ARID regions of each
representative subfamily member as indicated, pulled down with glutathione
beads, and analyzed by PAGE. Lane 1 shows the unselected pool of DNA
fragments. Remaining lanes show the fragments selected in Lambda DNA-
binding buffer with increasing KCl concentrations as indicated for p270, Dri
and MRF2. Each subfamily is indicated at the top with the particular
representative subfamily member assayed indicated directly below. The dots
on the right of the Dri panel designate the major bands that are consistently
selected by Dri in at least 10 repeats of this assay.
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criptional repressor in a reporter assay (34). Although jumonji
has JmJN and JmJC domains in common with the JARID1
subfamily, the members of JARID1 are more similar to each
other than to jumonji. Within the ARID domain, jumonji is
only about 25% identical to members of the JARID1 group,
which are 83% identical to each other. The jumonji ARID
domain binds DNA in the pull-down assay without detectable
sequence speciﬁcity (Figure 4). jumonji does show more of a
tendency than otherARID family members toretain binding to
lower molecular weight (<200 bp) DNA fragments even at
high stringency, suggesting it does not disassociate as rapidly
from DNA. This survey indicates that ﬁve of the seven ARID
subfamilies bind DNA with no obvious sequence speciﬁcity.
These results are summarized in Table 1.
The domains in the ARID1, ARID3 and ARID5 subfam-
ilies retain DNA-binding afﬁnity up to at least 200 mM KCl
concentration (Figure 3). DNA afﬁnity columns likewise
indicate that p270 and Dri have similar DNA-binding afﬁn-
ities [(11) and Figure 8]. ARID1B, which is closely related
overall to p270, retains DNA binding up to about 175 mM KCl
[(20) and additional data not shown]. JARID1 subfamily
domains also retain binding to at least 175 mM KCl
(Figure 4). However, the data in Figure 4 indicate that
ARID domains of the ARID2, ARID4 and JARID2 subfam-
ilies have relatively low DNA-binding afﬁnity. While this
assay is not a direct measure of afﬁnity, the results suggest
that there are three distinguishable categories in the ARID
family with regard to DNA-binding: sequence non-speciﬁc
with low afﬁnity, sequence non-speciﬁc with high afﬁnity and
sequence speciﬁc with high afﬁnity. Previously, we showed
that Saccharomyces cerevisieae SWI1 has relatively low
afﬁnity DNA-binding behavior that correlates with atypical
sequence in the Loop 2 and Helix 5 region (11). Current
results indicate that DNA-binding afﬁnity of ARID family
members can be low for reasons not easily apparent from
inspection of the ARID sequence.
Figure 4. DNA-binding properties of the ARID family. Representative members of the remaining subfamilies were assayed as indicated in the legend to Figure 3.
The unselected pool of DNA fragments is labeled Ladder and is shown for each individual experiment.
Table 1. Categorization of ARID subfamilies according to sequence
specificity
HUGO
nomenclature
Aliases Tissue specificity
AT-specific
ARID3A Bright, DRIL1, E2FBP1 Restricted (mature B
cells and testes) (3)
ARID3B Bdp, DRIL2 Broad (52)
ARID3C XM_071061 Not reported
ARID5A MRF-1 Not reported
ARID5B MRF2 Broad w/some specialization
[high in brain, kidney,
lung (39)]
Sequence non-specific
ARID1A p270, BAF250a, hOsa1,
OSA1, B120, hSWI1,
p250, SMARCF1
Broad (9,41,42,53,54)
ARID1B pKIAA1235, BAF250b,
p250R, hOsa2,
held/OSA1
Broad (41,42,55,56)
ARID2 pKIAA1557 Broad
a
ARID4A RBP1 Broad (57)
ARID4B RBP1L1, BCAA1, SAP180 Restricted (testes) (58)
JARID1A RBP2 Broad (57)
JARID1B PLU-1 Restricted (testes) (59)
JARID1C SMCX, XE169 Broad (28)
JARID1D SMCY, KIAA0234 Broad (28)
JARID2 jumonji Specialized [brain, heart,
skeletal muscles, kidney,
thymus (33)]
ahttp://www.kazusa.or.jp/huge/gfpage/KIAA1557
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on the identity of the specific major groove
contact residues of Dri
Inspection of the sequences in Figure 1 does not reveal any
obvious distinction between sequence-speciﬁc and sequence-
non-speciﬁc ARIDs. However,the structures ofthe MRF2, Dri
and p270 ARIDs have been solved in complex with DNA
(15,17,18). Each study agrees that a portion of the region
encompassing Loop 2 and/or Helix 5 lies within the major
groove (see Figure 5), and that regions upstream and/or down-
stream of the junction of Loop 2 and Helix 5 contact the minor
groove. The results have generated some ideas about the basis
for sequence speciﬁcity, but these have not yet been tested
empirically. Iwahara etal.(18) studied the DriARIDbyNMR,
and identiﬁed four residues in Loop 2 and Helix 5 of Dri that
make base-speciﬁc interactions in the major groove of the
DNA. These residues included two threonines (T), a serine
(S) and a phenylalanine (F), and are underlined in the Dri
ARID sequence shown in Figure 5. p270 has a serine (S) at
each of the corresponding positions. This study suggested that
the lack of the threonines and of a non-polar residue at the
phenylalanine position underlies the lack of sequence speci-
ﬁcity in p270.
We undertook a site-speciﬁc mutagenesis study to compare
the role of individual elements of the ARID in the determina-
tion of sequence speciﬁcity. The structures of the Dri and p270
ARIDs are the best characterized among their respective types
in regard to DNA interactions, so these domains were chosen
for comparison. To test whether the presence of the threonine
and phenylalanine residues in Helix 5 is sufﬁcient to confer
sequence speciﬁcity, we generated a mutant variant in which
threonines and a phenylalanine were introduced into the
appropriate positions in p270. The sequence of the resultant
mutant, designated p270.TFT, is shown in Figure 5.
The behavior of the p270.TFT mutant was examined in the
Lambda DNA pull-down assay. The results (Figure 6A) show
Figure 5. Sequences of the p270 and Dri mutants. The amino acid sequences of the wild-type p270 and Dri ARIDs are aligned. The Dri sequence is shown in blue
print. The p270 sequence is shownin red print, with identity to Dri shownin blue. The sequence shown for Dri is the expression product of plasmid p410.The p270
peptideusedintheseassaysistheexpressionproductofplasmidpNDB8,whichislongeroneachendthantheDripeptide.Thenumberofadditionalaminoacidson
each side is indicatedin the figure. For each sequence, the first residue is given a number corresponding to its position in the full-length protein (accession numbers
p270: NP_006006, Dri: AAB05771). The five residues that are invariant among all known ARID sequences are indicated by dots. The a-helices determined from
NMRstudiesareindicatedbygreyshadingandarenumbered(fromH0toH7)aboveeachsequence,alongwiththeloops(L1andL2)andb-sheet.BothDriandp270
ARIDs have been studied by NMR in complex with DNA (15,18).The Helix4–Loop2–Helix5 region is the helix–turn–helix motif that contacts the major groove in
bothproteins,althoughinp270Loop2contactsseemtocontributelessthaninDri.Theproteinsalsocontacttheadjacentminorgrooves.InDri,thishappensthrough
theb-sheetandtheendofHelix7.p270contactstheminorgrooveviatheLoop1regionthatcorrespondstotheb-sheet,buttheC-terminalareaofthep270ARIDdoes
notseemtocontributetoDNAbindingasmuchasthisregiondoesinDri.Additionally,aregionofabout15aminoacidsupstreamofp270Helix0interactswithDNA,
but a comparable contact site does not exist in Dri. According to the structural study of the Dri–DNA complex, four residues in the Loop2–Helix5 region, two
threonines (T), one serine (S) and one phenylalanine (F), make base-specific contacts. These residues and the corresponding residues in p270, all serines (S), are
indicatedbyunderlininginthefigure.Themutantpeptidesp270.TFT,Dri.SSS,p270.L2.TFTandp270.H4.L2.TFThavechangesonlyintheHelix4–Loop2–Helix5
regionandthereforeonlythatregionisshown.Forthein-framedeletionmutants,thewholesequenceisshown,withtheboundariesbetweendeletedsequencesshown
by the solid lines. For the p270.DN.L2.TFT mutant, residues from S993 to K1007 were deleted. For the Dri.DC and the Dri.SSS.DC mutants, residues from P378 to
N405 were deleted.
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tions do not confer any detectable capacity for sequence-
speciﬁc binding, even at the highest stringency.
We also generated the reverse substitution in the Dri
construct, replacing the presumptive base-speciﬁc contact
residues with serines. The sequence of the resultant mutant,
designated Dri.SSS, as shown in Figure 5, and the DNA-
binding behavior is shown in Figure 6B. Strikingly, the
Dri.SSS variant maintains a clear capacity for sequence-
speciﬁc binding, selecting a pattern of DNA fragments very
similar to those selected by wild-type Dri. It is apparent,
though, from the KCl titration in Figure 6B, that the Dri.SSS
variant has reduced overall afﬁnity for DNA. No DNA binding
is detected at this exposure in the 125 mM lane, while wild-
type Dri consistently shows detectable binding in similar
assays to at least 200 mM KCl (Figures 3 and 6B). The most
direct explanation for these results is that these positions in Dri
do make signiﬁcant DNA contacts that are important for
afﬁnity, but which are not major determinants of sequence
speciﬁcity. The DNA-binding afﬁnity of p270 is strong despite
thepresenceofserines atthesepositions, implyingthattherole
of individual positions is not neccesarily directly comparable
between different ARIDs.
The role of the helix–turn–helix motif
TheNMR-derivedp270structurewasreportedearlierthisyear
(15) and compared directly with the MRF2 structure (17). The
structure indicates that Helix 5 of p270 lies within the major
groove. However, these authors determined, by assessment of
changes in the dynamics of the complex, that the shorter Loop
2 of p270 is less ﬂexible than the corresponding loop in MRF2.
This suggested a ‘folding upon binding’ mechanism of
sequence recognition, in which the shorter length and/or
less ﬂexible composition of Loop 2 of p270 in comparison
to MRF2 and Dri affects orientation of the major groove con-
tact residues, and is thus responsible for lack of sequence-
speciﬁc contact.
p270 Loop 2 does not appear to contact DNA directly (15),
but to evaluate the possibility that Loop 2 affects the orienta-
tion of Helix 5 within the major groove, a p270 chimera was
constructed in which the Loop 2 sequence of Dri was
placed in the p270.TFT construct. This chimera, designated
p270.L2.TFT, contains the major groove contact residues of
Dri as well as a Loop 2 sequence derived entirely from Dri,
which, therefore, should be sufﬁciently long and ﬂexible to
permit proper orientation of the DNA contact residues within
the major groove. Nonetheless, when tested in the DNA pull-
down assay, the p270.L2.TFT chimera shows no greater tend-
ency to sequence speciﬁcity than wild-type p270, and, indeed,
has slightly less overall afﬁnity for DNA (Figure 7). Since the
TFT substitution alone did not affect p270 DNA-binding
afﬁnity, it is likely that the introduction of the exogenous
Loop 2 sequence created a distortion that interferes with
the overall strength of DNA contact in the p270 ARID.
A signiﬁcant difference between the way the p270 and Dri
ARIDs interact with DNA is that the p270 ARID has an
additional large minor groove interaction site just upstream
of Helix 0 (15). We considered the possibility that this region
of 15 amino acids interacts strongly and non-speciﬁcally with
DNA in a way that masks potential sequence-speciﬁcity in
p270. We therefore deleted this segment in the p270.L2.TFT
chimera to generate a new construct designated p270.
DL2.TFT. The DNA-binding afﬁnity of this fragment is
Figure 6. Assay of substitutions in the Helix 5 contact residues. The sequence specificity of the p270.TFT (A) and Dri.SSS (B) mutant peptides was tested in the
LambdaDNApull-downassayasdescribedinthelegendtoFigure3.Theprofilesofthewild-typep270andDripeptidesareshownforreference.Thedotsontheright
of the Dri panel designate the major bands that are consistently selected by Dri in this assay.
Nucleic Acids Research, 2005, Vol. 33, No. 1 73reduced still further, conﬁrming that the N-terminal region
contributes signiﬁcantly to DNA contact. However, the pep-
tide still shows little or no selection for speciﬁc fragments
(Figure 7). This argues against the possibility that sequence
selectivity was transferred by the introduction of the Loop 2
and Helix 5 residues of Dri, but was masked by the unique
N-terminal contact region of p270.
The ARID is categorized as a modiﬁed helix–turn–helix
motif-based DNA-binding domain, in which the second
helix of the motif (Helix 5) is the recognition helix. To test
the possibility that the ﬁrst helix of the motif (Helix 4) inﬂu-
ences the orientation of Loop 2 and the recognition helix, the
p270.L2.TFT construct was further modiﬁed such that the
entire region from the beginning of Helix 4 to the last
major groove contact residue consists of contiguous Dri
sequence. The name of this mutant is p270.H4.L2.TFT.
This construct still binds to DNA without any clear sequence
selectivity (Figure 7). Moreover, afﬁnity is reduced below that
of the p270.L2.TFT variant, supporting the suggestion above,
that introduction of exogenous sequence creates distortions
that interfere with the overall strength of DNA contact in
the p270ARID.Individualelementsarenotdirectlyexchange-
able between different ARIDs. Together, these results indicate
that sequence speciﬁcity in the ARID does not depend solely
on the speciﬁc amino acid composition in the major groove
contact region.
Contribution of the extended ARID region
Members of the ARID3 subfamily in all species studied are
characterized by the presence of an ‘extended’ ARID
sequence, a region of very high identity (>70% identity across
 35 residues) immediately following the core ARID
consensus (see Figure 1). This region includes Helix 7,
which is so far unique to the ARID3 subfamily, and extends
beyond it. The extended ARID region has been identiﬁed as a
DNA contact region in Dri (18). The extended ARID sequence
is not present in the ARID5 subfamily, so cannot be a required
determinant of sequence speciﬁcity. However, a correspond-
ing position C-terminal to the core ARID consensus in MRF2
has been identiﬁed as a DNA contact region (17). In contrast,
the corresponding region in p270 does not appear to make
signiﬁcant DNA contact (15). To assess the contribution of
this region of Dri to sequence speciﬁcity, an in-frame deletion
of sequence encoding 28 amino acids was generated in this
region. The resulting mutant is designated Dri.DC. The DNA
pull-down assay indicates that this construct retains a consid-
erable measure of sequence selectivity (Figure 8). The con-
struct shows slightly reduced DNA-binding afﬁnity, consistent
with the interpretation that the deleted region includes a DNA
contact site.
The deletion of the extended ARID was also engineered in
the Dri.SSS background. The resulting mutant is designated
Dri.SSS.DC. In the DNA pull-down assay, the Dri.SSS.DC
construct (Figure 8) has the same reduced DNA-binding
afﬁnity as was seen in the Dri.SSS mutant in Figure 6B.
The sequence selectivity is further reduced, but a weak select-
ivity is still evident.
The lambda DNA restriction fragment pool was used as the
target DNA in order to offer a wide range of sequence pos-
sibilities to the ARID proteins used in this survey. This
allowed for the possibility that some family members, or some
mutant variants, would show sequence preference, but for a
previously unrecognized sequence. However, a disadvantage
Figure 7. Assay of p270/Dri chimeras. The sequence specificity of the
p270.L2.TFT, p270.DN.L2.TFT and p270.H4.L2.TFT mutant peptides was
tested with the Lambda DNA pull-down assay as described in the legend to
Figure 3. The GST DNA-binding profile is shown as a control.
Figure 8. Deletion of the ARID3 extended sequence. The sequence specificity
of the Dri.DC and Dri.SSS.DC mutant peptides was tested with the Lambda
DNA pull-down assay as described in the legendto Figure 3. The profile of the
wild-type Dri, along with the markers for the major bands selected by Dri, are
also shown for reference.
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plex restriction pattern precludes the identiﬁcation of indi-
vidual restriction fragments, or the actual sequence of the
selectedfragments.Toobtainamorequantitativemeasurement
of sequence speciﬁcity, selected mutants were probed in an
oligonucleotide competition assay, where their afﬁnity for a
Dri consensus binding site (CCAATTAATCCC) was com-
pared with their afﬁnity for an altered consensus site
(CCAATTGCTCCC). The consensus sites were synthesized
as three tandem repeats. This assay was performed in low
salt (50 mM) conditions, so that the effect of increasing salt
concentrations onthe conformationoftheproteinwouldnotbe
afactorintheassay.TheresultsareshowninFigure9A.TheDri
peptideshowsaclearpreferenceforitsidentiﬁedconsensussite
in this assay, as reported previously (4). A 500-fold excess of
cold competitor with the correct consensus sequence competes
effectively with the labeled probe, while the altered sequence,
even at 1000-fold excess, shows little ability to displace the
peptide(Figure9A,panel2).Incontrast,theAT-richconsensus
site does not compete for p270 binding any better than the
mutant oligonucleotide (Figure 9A, panel 1).
The Dri.SSS and Dri.DC variants were both tested in this
assay. The results show that each has a higher preference for
the AT-rich consensus site than for the altered oligonucleotide
(Figure 9A, panels 3 and 4), meaning that they clearly retain
sequence-speciﬁc binding. This is consistent with the behavior
they showed in Figures 6B and 8.
When we attempted this assay with the Dri.SSS.DC con-
struct, we found that the peptide bound poorly to the oligo-
nucleotide even at 50 mM salt. Because the ARID proteins
show a generally higher afﬁnity for longer pieces of DNA, we
attempted the assay with a longer oligonucleotide, containing
eight repeats of the consensus sequence rather than three. The
Dri.SSS.DCpeptideboundwelltothisprobe(Figure9B).Wild-
type Dri showed the same behavior on this probe as on the
shorterone:itwasdisplacedmorereadilybythetrueconsensus
sequencethanbythealteredsequence(Figure9B,panel1).The
Dri.SSS.DCpeptideshowedlessspeciﬁcitythanwild-typeDri,
but a weak selectivity was still evident (Figure 9B, panel 2),
consistent with the behavior seen in Figure 8.
The DNA-binding phenotype of the double mutant,
Dri.SSS.DC, implies that the region C-terminal to the core
ARID consensus, and amino acid identity at the major groove
contact site, contribute to the presence of sequence speciﬁcity
in ARID3 subfamily proteins, but do not support a conclusion
that small amino acid differences, such as the identity of
residues at the junction of Loop 2 and Helix 5, or the length
of Loop 2, are the principal determinants of sequence speci-
ﬁcity. Rather, the results suggest that overall differences in the
three-dimensional structure of individual ARID subfamilies
determines the presence of sequence speciﬁcity. A similar
situation appears to hold for the distinction between
sequence-speciﬁc and sequence-non-speciﬁc DNA binding
inHMGdomainproteins,consideredfurther inthe Discussion.
p270 and Dri differ in their ability to tolerate
mutations in the aromatic scaffold
The potential for differences in the overall structure of the
p270 and Dri ARIDs was probed by introducing changes into
the aromatic scaffold of the two domains. Within the core
consensus sequence, there are ﬁve invariant amino acids
that are almost identically spaced across each ARID. These
are indicated by red text in Figure 1 and dots in Figure 4, and
include a tryptophan (W) in Helix 4, a tyrosine (Y) in Helix 5
and a proline (P) in Loop 1. The presence of a series of
invariant aromatic residues has been recognized as a structural
scaffold in other helix–turn–helix motifs, including the DNA-
binding motif in c-Myb and the homeodomain (35,36).
To test the contribution of the invariant residues in the
ARID structure, speciﬁc invariant residues were changed to
the small neutral residue alanine in the ARIDs of both Dri
and p270. The resultant wild-type and mutant peptides were
translated in vitro, and their DNA-binding afﬁnity was
assessed using a sensitive and quantitative DNA afﬁnity
column chromatography assay described previously (9,11).
Because the DNA is in large excess, the assay is unbiased
with respect to sequence speciﬁcity. The results are shown in
Figure 10.
The interaction of the wild-type p270 ARID-containing
peptide with DNA is as strong as that of the wild-type Dri
ARID-containing peptide. In both wild-type proteins, 80–90%
of the signal is retained on the columns. The remainder comes
off in the ﬂow-through and the ﬁrst wash, and presumably
represents a fraction of peptide that did not bind due to
impaired folding. The proline-to-alanine substitution has
very little effect on the elution proﬁle of either p270 or Dri,
suggesting that this residue, though invariant, is not by
itself critical for the maintenance of structural integrity in
the domain.
On the other hand, the Helix 4 tryptophan-to-alanine sub-
stitution seriously impaired binding to native DNA in both
Figure 9. Competition assay with the Dri mutants. The competition assays
show binding of the GST-fusion peptides to a labeled oligonucleotide
containing a consensus sequence for Dri. All reactions contain a 10000-fold
excess of salmon sperm DNA. Binding to the consensus sequence was
competed with increasing amounts of unlabeled specific competitor, either
the consensus sequence (wild-type) or an altered sequence (mutant) in a
10-fold, 50-fold, 100-fold, 500-fold or 1000-fold excess. A separate reaction
was used in each experiment with just glutathione–agarose beads as a control.
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p270 or Dri) fails to bind to the column and is recovered in the
ﬂow-through and wash fractions. The strongly deleterious
effect of the tryptophan substitution suggests that the invari-
able tryptophan plays a critical role in maintaining the overall
integrity of the ARID structure in both sequence-speciﬁc and
sequence-non-speciﬁc representatives of the family.
p270 and Dri showed a different tolerance to the third
mutation, a tyrosine-to-alanine substitution in Helix-5. The
elution proﬁle of the p270 mutant peptide is similar to that
Figure10.Substitutionofinvariantresidues.Thestrengthoftheinteractionofthewild-typep270andDripeptides,aswellaspeptideswhereinvariantresidueswere
substituted by an alanine, was tested by DNA affinity chromatography. In vitro translated 35S-methionine-labeled peptides were applied to a native DNA cellulose
columnasdescribedinMaterialsandMethods.BoundproteinwaselutedstepwisewithloadingbufferadjustedtocontainincreasingconcentrationsofNaClfrom100
to 800 mM,asindicated inthe figure.FractionswereseparatedbySDS–PAGEandthe p270signalineach fractionwasquantifiedby phosphorimaging.The results
areplottedasthepercentageofsignalineachfractionrelativetotheentiresignalrecovered.Eachexperimentwasperformedatleasttwiceandtheerrorbarsrepresent
the average deviation. Graphs are aligned for ease of comparison. The dashed line indicates the second 200 mM fraction for reference.
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signal is retained on the column, although the shift in the
elution peak from the second to the ﬁrst 200 mM fraction
indicates a weakening of afﬁnity. This type of elution proﬁle
suggests that the substitution causes loss of one or more DNA
contact sites, but does not suggest that protein folding is
grossly affected. In contrast, the corresponding substitution
in Dri is as deleterious as the tryptophan substitution, with
40–50% of the signal failing to bind to the column, implying
that this residue is critical in the Dri ARID for maintaining
proper structure.
To probe further the role of the Helix 5 tyrosine in the p270
ARID, the Y1096A substitution was combined with the
P1042A substitution. The effect of the combined mutations
was highly synergistic (Figure 11), generating a DNA-binding
proﬁle almost as defective as that seen with the W1073A
substitution. This conﬁrms that the Helix 5 tyrosine is
important to structural integrity in the p270 ARID, but the
results suggest that the p270 ARID is more able than the
Dri ARID to tolerate changes in its aromatic scaffold.
Thus, there appear to be fundamental differences in the
ARID structures of p270 and Dri that go beyond simple
differences at speciﬁc amino acid positions. This is consistent
with the detrimental effects observed above of exchanging
presumably analogous sequences between the two proteins.
The mutagenesis studies argue against a conclusion that
speciﬁc amino acids in Loop 2 or Helix 5 are the main
determinants of sequence speciﬁcity. Most probably, this is
determined by multiple interacting differences across the
entire ARID structure.
DISCUSSION
The overall conclusion from the survey described here is that
the majority of ARID subfamily domains bind DNA without
regard to sequence speciﬁcity. Thus, the acronym is somewhat
of a misnomer, although it is a well established and useful
descriptor for a domain whose parameters are well-deﬁned.
This survey did not probe the behavior of every single member
of the human ARID family. The proteins that have not been
tested directly, here or elsewhere, among the subfamilies now
designated as sequence non-speciﬁc are RBP1L1 (ARID4B),
SMCX and SMCY (JARID1C and JARID1D). Each of these
shows at least 75% identity and even greater similarity to the
tested members of its subfamily. In addition, a mention of data
not shown in a report on RBP1L1 (syn:SAP180) notes that a
high-afﬁnity consensus binding site could not be found in
DNA-binding site selection experiments (25). Among the sub-
families now designated as AT-speciﬁc, only DRIL2
(ARID3B) and ARID3C have not been tested empirically,
but again, there is at least 75% identity and more than 90%
similarity between these ARID sequences and the AT-speciﬁc
prototypes Bright and Dri. There is a potential conﬂict
between our conclusions and a report suggesting that an
ARID-containing fusion peptide of jumonji (JARID2) may
have general selectivity for AT-rich sequences, since a
majority of sequences selected by jumonji from a pool of
random oligonucleotides were AT rich (34). However, several
sequences that jumonji bound with equally high afﬁnity in that
study were not AT rich, and a precise consensus site could not
be identiﬁed. The present survey is concerned with the prop-
erties inherent in the ARID sequence from each subfamily. As
such, it was conducted with fusion proteins expressing the
respective ARID sequences separate from the context of the
native proteins. It remains possible that the endogenous
proteins acquire a degree of sequence-speciﬁc binding beha-
vior in physiological conditions.
The emergence of speciﬁc ARID subfamilies appears to
have occurred early in evolution. S.cerevisieae encodes two
ARID proteins. The ARID sequences do not correlate closely
with any particular human subfamily, but overall the proteins
seem most similar to the ARID1 and JARID1 subfamilies.
Schizosaccharomyces pombe encodes four ARID proteins,
two that are members of chromatin remodeling complexes
and two that share similarity to the JARID1 subfamily.
Ceanorhabditis elegans encodes four ARID proteins, aligning
with human subfamilies ARID1, ARID2, ARID3 and JARID1,
thus including a single AT-speciﬁc subfamily representative
(for an excellent review of ARID evolution see http://www.
lifesci.utexas.edu/research/tuckerlab/bright/evolution/). The
ARID protein CFI-1 is the only identiﬁed member of an
ARID3-type subfamily within C.elegans and prefers the
same AT-rich consensus sequence as Dri in a competition
assay (37). Drosophila melanogaster encodes six ARID
proteins, one aligning with each subfamily except the second
AT-richspeciﬁcsubfamilyARID5.Thesepatternssuggestthat
Figure 11. Combination of the proline and tyrosine substitutions can act
synergistically to impair p270 ARID binding to DNA. The strength of the
interaction of the combined substitution mutant was tested by DNA affinity
chromatographyasdescribedabove.Theelutionprofileofthewild-typep270is
repeated in this panel and the graphs are aligned for ease of comparison. The
dashed line indicates the second 200 mM fraction for reference.
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property of sequence speciﬁcity through evolution.
The precise function of all the human ARID proteins is not
known. Members of the AT-speciﬁc ARID3 and ARID5
subfamilies are sequence-speciﬁc transcription factors with
recognized promoter targeting functions and important roles
in development and differentiation (3,4,5,38–40). Among the
sequence-non-speciﬁc ARID proteins, several appear to par-
ticipate in general transcription and chromatin remodeling
functions. ARID1A and ARID1B are mutually alternative
members of human SWI/SNF-related complexes (20,41,42)
and ARID1A (p270) is implicated in the tumor suppressor
activity of the complexes (43). Human ARID2 is uncharacter-
ized, but the Drosophila ortholog of ARID2 is a member of a
SWI/SNF-like complex (22). ARID4A and ARID4B can
associate with the mSIN3-histone deacetylase complex
(19,25). Members of the JARID1 and JARID2 subfamilies
show transcription activation and/or repression functions
(26,27,34). To date, only the Dri and Bright (ARID3A)
ARIDshave actuallybeen shown tobe requiredforthe physio-
logicalfunctionoftheir cognate proteins(44,45).TheARIDof
the S.cerevisieae protein SWI1 appears dispensable for com-
plementation of the SWI1 phenotype (46), but transient
reporter assays suggest the ARID is required for a transactiva-
tion function in human ARID1B (41). More physiological
experiments are needed.
Site-speciﬁc mutagenesis has not revealed any precise
determinants for sequence speciﬁcity or lack of it within
the ARID family. Most probably, this is determined by mul-
tiple interacting differences across the entire ARID structure.
A similar situation appears to hold for the distinction between
sequence-speciﬁc and sequence-non-speciﬁc DNA binding in
high mobility group (HMG) domain proteins. HMG domain
containing proteins bind DNA through contacts in the minor
groove. They recognize DNA structures such as four-way
junctions, distorted cisplatin-kinked DNA and supercoiled
DNA, and generally have the ability to bend DNA. One
HMG protein subfamily consists of transcription factors
like LEF-1 (lymphoid enhancer factor-1) and SRY (mamma-
lian sex determining gene) that bind sequence speciﬁcally to
AT-rich sequences in enhancer and promoter regions. Mem-
bers of this subfamily contain one copy of the HMG domain
and are tissue speciﬁc. Another subfamily comprises chromo-
somal proteins such as HMG1 and HMG2 that bind DNA in a
sequence-non-speciﬁc manner. These proteins generally con-
tain twoormore HMGdomains (47,48).There isahighdegree
of sequence similarity and structural characteristics between
the sequence-speciﬁc and the sequence-non-speciﬁc HMG
domains in complex with DNA. Some highly conserved
residues have been identiﬁed as very important in sequence
speciﬁcity of HMG domains, but these residues alone are not
the soledeterminant ofsequencespeciﬁcity[reviewedin(47)].
Rather, sequence-speciﬁcity appears to be a combination of
effects of residues on the domain’s positioning, afﬁnity, its
stability in complex with DNA, the number of interactions on
the protein–DNA interface and the number of base-speciﬁc
contacts (49). Studies of the HMG domain indicate the
difference between sequence-speciﬁc and sequence-non-
speciﬁc members of the same family is generally more
complex than the simple substitution of contact residues for
neutral residues.
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